Clinical trialNCT02915172WithdrawnPhase 1Interventional

Lenvatinib and Capecitabine in Patients With Advanced Malignancies

SponsorM.D. Anderson Cancer CenterEnrollment0Advanced CancerMalignant Neoplasm of BreastMalignant Neoplasms of Bone and Articular CartilageMalignant Neoplasms of Digestive OrgansMalignant Neoplasms of Eye Brain and Other Parts of Central Nervous SystemMalignant Neoplasms of Female Genital Organs+8 more conditions

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

David S. Hong, MD
M.D. Anderson Cancer Center
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

No facility list is in our current data snapshot for this study. The registry record on ClinicalTrials.gov ↗ carries any published locations. Why? →

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Capecitabine →Lenvatinib →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Dec 2016
Primary completion: 31 Dec 2022
Completion: —
Last update posted: 26 Jun 2017
Registered enrollment: 0
Registry id: NCT02915172

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.